Filing Details
- Accession Number:
- 0001209191-23-050282
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-21 16:35:11
- Reporting Period:
- 2023-09-20
- Accepted Time:
- 2023-09-21 16:35:11
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1231457 | Genelux Corp | GNLX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1937482 | Yong Yu | C/O Genelux Corporation 2625 Townsgate Road, Suite 230 Westlake Village CA 91361 | Vp, Clinical Trial Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-09-20 | 6,000 | $6.00 | 112,135 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-09-20 | 6,000 | $27.96 | 106,135 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2023-09-20 | 6,000 | $0.00 | 6,000 | $6.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
223,253 | 2029-09-20 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023.
- The weighted average sale price for the transaction reported was $27.9643, and the range of prices were between $27.95 and $28.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- Immediately exercisable.